SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
NEW YORK, Jan. 29, 2018 -- On January 19, 2018, Safirstein Metcalf LLP and HGT Law commenced a shareholder “opt-out” lawsuit (“Lawsuit”) on behalf of a group of retail investors (“Investors”) against Valeant Pharmaceuticals International, Inc. (“Valeant”) (NYSE:VRX) and its senior officers for violations of federal securities laws.
Previously, on June 24, 2016, a class action complaint was filed in the U.S. District Court for the District of New Jersey, on behalf of a class consisting of all purchasers of the common stock of Valeant (“Class Action”). The Investors have opted out of the Class Action to directly pursue their own claims. To date, this Lawsuit is the only opt-out action that has been filed on behalf of retail investors.
A copy of the complaint filed by Safirstein Metcalf LLP and HGT Law on behalf of the Investors can be found at www.valeantshareholderlitigation.com
If you purchased Valeant common stock during the Class Period and suffered losses of more than $200,000, then you may wish to consider opting out of the existing class action. If you would like to learn about the options available to you, please call 1-800-221-0015, email [email protected] or visit www.valeantshareholderlitigation.com
The class action is brought on behalf of purchasers of Valeant equity securities and senior notes between January 4, 2013 and March 15, 2016 (the “Class Period”).
| Company: | Valeant Pharmaceuticals International, Inc. |
| Exchange: | NYSE |
| Ticker: | VRX |
| Class Period: | 01/04/2013 – 03/15/2016 |
About Safirstein Metcalf LLP and HGT Law
Safirstein Metcalf LLP focuses its practice on shareholder rights. The law firm also practices in the areas of antitrust and consumer protection. All of the Firm’s legal endeavors are rooted in its core mission: provide investor and consumer protection.
HGT Law is a boutique commercial litigation firm based in New York. The firm focuses on representing investors in securities litigation and corporate governance/derivative litigation.
Attorney advertising. Prior results do not guarantee a similar outcome.
Safirstein Metcalf LLP
Peter Safirstein, Esq.
1250 Broadway
27th Floor
New York, NY 10001
1-800-221-0015
